IRIS Accounts Production v23.3.0.418 04210685 Board of Directors 1.7.22 30.6.23 30.6.23 true false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh042106852022-06-30042106852023-06-30042106852022-07-012023-06-30042106852021-06-30042106852021-07-012022-06-30042106852022-06-3004210685ns10:Originalns15:EnglandWales2022-07-012023-06-3004210685ns14:PoundSterlingns10:Original2022-07-012023-06-3004210685ns10:Originalns10:Director12022-07-012023-06-3004210685ns10:Original2022-07-012023-06-3004210685ns10:Original2023-06-3004210685ns10:Originalns10:PrivateLimitedCompanyLtd2022-07-012023-06-3004210685ns10:Originalns10:SmallEntities2022-07-012023-06-3004210685ns10:Originalns10:AuditExempt-NoAccountantsReport2022-07-012023-06-3004210685ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3004210685ns10:SmallCompaniesRegimeForAccountsns10:Original2022-07-012023-06-3004210685ns10:Originalns10:FullAccounts2022-07-012023-06-3004210685ns10:Original12022-07-012023-06-3004210685ns10:Original2022-06-3004210685ns10:Originalns5:CurrentFinancialInstruments2023-06-3004210685ns10:Originalns5:CurrentFinancialInstruments2022-06-3004210685ns10:Originalns5:Non-currentFinancialInstruments2023-06-3004210685ns10:Originalns5:Non-currentFinancialInstruments2022-06-3004210685ns5:ShareCapitalns10:Original2023-06-3004210685ns5:ShareCapitalns10:Original2022-06-3004210685ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-06-3004210685ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-06-3004210685ns10:Originalns10:RegisteredOffice2022-07-012023-06-3004210685ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-07-012023-06-3004210685ns10:Originalns5:PlantMachinery2022-07-012023-06-3004210685ns10:Originalns5:FurnitureFittings2022-07-012023-06-3004210685ns10:Originalns5:ComputerEquipment2022-07-012023-06-3004210685ns10:Original2021-07-012022-06-3004210685ns10:Originalns5:NetGoodwill2022-06-3004210685ns10:Originalns5:NetGoodwill2023-06-3004210685ns10:Originalns5:NetGoodwill2022-06-3004210685ns10:Originalns5:PlantMachinery2022-06-3004210685ns10:Originalns5:PlantMachinery2023-06-3004210685ns10:Originalns5:PlantMachinery2022-06-3004210685ns10:Originalns5:CostValuation2022-06-3004210685ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-06-3004210685ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-06-30
REGISTERED NUMBER: 04210685 (England and Wales)


















Unaudited Financial Statements for the Year Ended 30 June 2023

for

ADAllen Pharma Limited

ADAllen Pharma Limited (Registered number: 04210685)






Contents of the Financial Statements
for the Year Ended 30 June 2023




Page

Balance Sheet 1

Notes to the Financial Statements 3


ADAllen Pharma Limited (Registered number: 04210685)

Balance Sheet
30 June 2023

2023 2022
Notes £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 9,390 15,344
Investments 6 100 100
9,490 15,444

CURRENT ASSETS
Stocks 38,535 18,100
Debtors 7 307,120 782,720
Cash at bank and in hand 1,398,691 1,479,672
1,744,346 2,280,492
CREDITORS
Amounts falling due within one year 8 (483,088 ) (1,010,709 )
NET CURRENT ASSETS 1,261,258 1,269,783
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,270,748

1,285,227

CREDITORS
Amounts falling due after more than one
year

9

-

(30,833

)
NET ASSETS 1,270,748 1,254,394

CAPITAL AND RESERVES
Called up share capital 201 201
Retained earnings 1,270,547 1,254,193
1,270,748 1,254,394

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ADAllen Pharma Limited (Registered number: 04210685)

Balance Sheet - continued
30 June 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit & Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 October 2023 and were signed on its behalf by:





R O Allen - Director


ADAllen Pharma Limited (Registered number: 04210685)

Notes to the Financial Statements
for the Year Ended 30 June 2023

1. STATUTORY INFORMATION

ADAllen Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 04210685

Registered office: Treviot House
186-192 High Road
Ilford
Essex
IG1 1LR

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

Consolidated financial statements
The financial statements contain information about ADAllen Pharma Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Consolidated financial statements are not prepared by the company on the grounds that the company qualifies as a small company.

Turnover
Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance
Fixtures and fittings - 25% on reducing balance
Computer equipment - 33% on reducing balance

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Inventories
Inventories have be valued at the lower of cost and estimated selling price less costs to sell. In respect of work in progress and finished goods, costs include a relevant proportion of overheads according to completion.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit & Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

ADAllen Pharma Limited (Registered number: 04210685)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2022 - 7 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 July 2022
and 30 June 2023 90,000
AMORTISATION
At 1 July 2022
and 30 June 2023 90,000
NET BOOK VALUE
At 30 June 2023 -
At 30 June 2022 -

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 July 2022 223,451
Additions 1,299
At 30 June 2023 224,750
DEPRECIATION
At 1 July 2022 208,107
Charge for year 7,253
At 30 June 2023 215,360
NET BOOK VALUE
At 30 June 2023 9,390
At 30 June 2022 15,344

ADAllen Pharma Limited (Registered number: 04210685)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

6. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 July 2022
and 30 June 2023 100
NET BOOK VALUE
At 30 June 2023 100
At 30 June 2022 100

7. DEBTORS
2023 2022
£    £   
Amounts falling due within one year:
Trade debtors 138,082 450,995
Amounts owed by subsidiary undertaking 108,300 50,000
Other debtors 15,572 23,317
261,954 524,312

Amounts falling due after more than one year:
Amounts owed by subsidiary undertaking 45,166 258,408

Aggregate amounts 307,120 782,720

The debts that were subject to invoice discounting for the company at the year end amounted to £43,192.

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Bank loans and overdrafts - 10,000
Trade creditors 107,497 678,947
Taxation and social security 93,955 80,433
Other creditors 281,636 241,329
483,088 1,010,709

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Bank loans - 30,833

10. SECURED DEBTS

Lloyds bank commercial finance limited has a fixed and floating charge against all the business assets.